27
Participants
Start Date
December 31, 2009
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
Xolair placebo
two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Xolair (omalizumab)
two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Massachusetts General Hospital, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER